Comparative Pharmacology
Head-to-head clinical analysis: QDOLO versus SUFENTANIL CITRATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QDOLO versus SUFENTANIL CITRATE.
QDOLO vs SUFENTANIL CITRATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
Selective mu-opioid receptor agonist; inhibits ascending pain pathways and alters pain perception and emotional response to pain.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
0.5-5 mcg/kg IV/IM for induction of anesthesia; 0.1-0.3 mcg/kg IV for epidural analgesia; 0.3-0.8 mcg/kg IV for short operative procedures; maintenance with 0.1-0.3 mcg/kg IV every 1-2 hours as needed.
None Documented
None Documented
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Terminal elimination half-life: 2-4 hours (adults), 1-3 hours (neonates), 3-6 hours (elderly). Context: context-sensitive half-time increases with infusion duration.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Renal (metabolites, <1% unchanged); fecal (biliary elimination of metabolites); approximately 80% renal, 20% fecal.
Category C
Category D/X
Opioid Agonist
Opioid Agonist